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httpense.Abstract Introduction: Statins are now becoming recognized as powerful antiinﬂammatory agents
that exert beneﬁcial effects beyond low-density lipoprotein cholesterol reduction [1].
COPD patients receiving statins obtain a beneﬁt from these therapeutic agents. Clearly, the best
medical evidence for the association of statins with improved outcomes for COPD patients [2].
We aimed in this study to assess anti inﬂammatory effects of statin in COPD patients.
Patients and methods: We studied 28 patients with chronic obstructive lung disease. Fourteen
patients (11 male and 3 female) receiving statin due to hyperlipidemia (9 patients received simvasta-
tin and 5 patients atorvastatin), and other 14 patients (11 male and 3 female) not hyperlipidemic. All
patients were subjected to Pulmonary function (spirometery) pre and at end of study. Sputum
induction before and at end of 10 months from statin starting, and determination of leptin, total
and differential cell count pre and at end of study.
Results: After 10 months from statin intake we found signiﬁcant decrease of TCC in statin grou-
pand also high signiﬁcant decrease of sputum leptin, neutrophils, and COPD exacerbation in the
same group when compared to control group. And signiﬁcant decrease of TCC in statin group
pre and at end of study with high signiﬁcant decreases of sputum leptin, neutrophils, and COPD
exacerbation of statin group pre and 10 months of statin intake. Titropium bromide has positive
signiﬁcant effects on sputum leptin in statin group.
Conclusion: We conclude that statin may lower the exacerbation in patients with chronic
obstructive lung diseases and may lower the total cell count of inﬂammatory cells, sputum leptin
and neutrophils.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.01063840128.
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COPD is a common preventable and treatable disease is char-
acterized by persistent airﬂow limitation that is usually pro-
gressive and associated with enhanced chronic inﬂammatory
response in the airway and the lung to noxious particles and
gases exacerbations and co morbidity contribute to overall
severity in individual patient [17].is. Production and hosting by Elsevier B.V.
1.006
66 N.A. Rezk, A. ElewaStatins, inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme
A reductase, are potent inhibitors of cholesterol biosynthesis
and have greatly improved the management of ischaemic heart
disease. Recent studies suggest that direct antithrombotic and
anti-inﬂammatory effects associated with treatment with
statins may at least partly account for the reduction of
cardiovascular events. In particular,statins reduce high
sensitive C reactive protein (hs-CRP), tumour necrosis factor
a, and metalloproteinase 9 production [3].
Statins are nowbecoming recognized as powerful antiinﬂam-
matory agents that exert beneﬁcial effects beyond low-density
lipoprotein cholesterol reduction. Upregulation of endothelial
function (i.e., eNOS enzyme activity) is thought to be a primary
mechanism responsible for these antiinﬂammatory properties.
Pruefer et al. [6] now provide additional evidence that statin
therapy attenuates inﬂammation and further extend out under-
standing of this very exciting class of cardiovascular agents [1].
Recently it has been shown that statins can modify the bal-
ance of T helper subset 1 (Th 1) and 2 (Th 2) cells by inhibition
of Th1 development and augmentation of Th 2 development of
CD4+ T cells [4]. In the present observational retrospective
study we observed a relation between statin use and frequency
of an unusual Th1 subset of T lymphocytes, CD4 + CD28
null, which is often expanded in unstable angina [5].
We aimed in this study to assess anti inﬂammatory effects
of statin in COPD patients.
Patients and methods
We studied 28 patients with chronic obstructive lung disease.
Fourteen patients (11 male and 3 female) receiving statin due
to hyperlipidemia (9 patients received simvastatin and 5 pa-
tients atorvastatin), and other 14 patients patients (11 male
and 3 female) not hyperlipidemic.
All patients underwent all of the following
1 Complete history and clinical examination.
2 Routine investigations, CBC, LFT, RFT, lipid proﬁle.
3 FEV1 pre and post bronchodilator.
4 Pulmonary function (spirometery) pre and at end of study.
5 Sputum induction before and at end of 10 months from sta-
tin starting and determination of leptin, total and differen-
tial cell count pre and at end of study.Exclusion criteria
1 Any patients whose statin therapy had been interrupted
2 who had a concomitant diagnosis of congestive heart
failure
3 radiographic evidence of pneumonia
4 Uncooperative patients.
5 Patients subjects on long-term oral corticosteroids
6 those with a FEV1, predicted, of <20% or a life expec-
tancy of <1 year.Sputum induction [6]
Sputum was induced via inhalation of a hypertonic saline aero-
sol, generated by an ultrasonic nebulizer. Solutions of sodium
chloride 5%, 6 ml divided to three 2 ml were nebulized at roomtemperature for 7 min each. Subjects then inhaled the hyper-
tonic saline aerosols for three periods of 7 min. Following each
period of hypertonic inhalation, subjects were asked to blow
their nose and to rinse their mouth and gargle their throat thor-
oughly with water. They were then encouraged to cough and
expectorate sputum into a sterile plastic container, which was
kept on ice. The procedure was terminated after three periods
of 7 min or after a fall in FEV1 of 20% from the baseline value.
Sputum processing [6]
Sputum was processed within 15 min after termination of the
induction. The volume of the whole sputum sample was deter-
mined, and an equal volume of 0.1% dithiothreitol was added.
The samples were agitated on a vortex mixer in a wide-bore
plastic test tube and placed in a shaking water bath for
15 min at 37 C to ensure complete homogenization.
The samples were then ﬁltered through 48-mm nylon gauze
(Thompson, Ontario, Canada) and agitated on a vortex mixer.
A total cell count (TCC) was performed on the ﬁltered sample
and viability was checked by means of trypan blue exclusion.
The ﬁltered sample was centrifuged for 5 min at 5906g at
48 C. The supernatant was aspirated and stored in Eppendorf
tubes at 808 C. The cell pellet was resuspended in ﬂuores-
cence-activated cell sorter (FACS) buffer (0.5% bovine serum
albumin in phosphate-buffered saline (pH 7.4 ± 7.6)) to a con-
centration of 0.46106 cells mL1 and cytospins preparations
were performed by putting 100 mL of the cell suspension in
the funnels and centrifuging for 5 min at 236g with low decel-
eration. Two cytospin slides for differential cell counts were
stained with May-GruE`nwald Giemsa (MGG). Differential
cell counts were performed by counting 300 non squamous
cells in each coded MGG cytospin preparation in a blinded
fashion by two technicians. The mean of both scores was used
for analysis. Absolute cell numbers per milliliter of sputum
were calculated by multiplying the cell percentage by the total
(non squamous) cell number in the sputum, divided by the vol-
ume of the sputum sample in milliliters.
Spirometery technique [7]
Subject preparation
Activities that should preferably be avoided prior to lung func-
tion testing:
1 Smoking within at least 1 h of testing
2 Consuming alcohol within 4 h of testing
3 Performing vigorous exercise within 30 min of testing
4 Wearing clothing that substantially restricts full chest and
abdominal expansion
5 Eating a large meal within 2 h of testing
Recommendation: vital capacity (VC) [8]
VC= The maximal volume of air exhaled from the point of
maximal inhalation or the maximal volume of air inhaled from
a point of maximal exhalation can be measured with a slow
exhalation or inhalation, respectively. This was previously
called the ‘‘slow’’ vital capacity and has been better described
as the ‘‘relaxed vital capacity’’ [13]. The VC is expressed in
liters (BTPS).
Anti inﬂammatory effects of statin in COPD 67Recommendation: forced vital capacity (FVC) [8]
FVC=Maximal volume of air exhaled with maximally forced
effort from a position of maximal inspiration, i.e., vital
capacity performed with a maximally forced expiratory effort,
expressed in liters (BPS) Tables 1–5.
Recommendation: timed forced expiratory volume (FE&)
FEV=The volume of air exhaled in the speciﬁed time during
the performance of the FVC, e.g., FEV, for the volume of air ex-
haled during the ﬁrst second of FVC, expressed in liters (BTPS).
*Data was analyzed using SPSS (Statistical Package for So-
cial Sciences) version 15. Qualitative data was presented as
number and percent. Comparison between groups was done
by Chi-Square test. Data was presented as mean ± SD. Paired
t-test was used for comparison within groups. Student t-test
was used to compare between two groups. P< 0.05 was con-
sidered to be statistically signiﬁcant.Results
There is no signiﬁcance differences between the two groups re-
garded to age, pulmonary function, leptin, total, differentialTable 1 Statin and control groups before introduction of statin.
Statin (n= 14)
AGE 57.29 ± 6.50
FEV1 pre 47.21 ± 9.58
FEF25pre 59.86 ± 6.13
FEF50pre 54.07 ± 6.73
FEF75pre 36.50 ± 6.44
lePtin pre (pg/ml) 181.29 ± 49.02
TCC 106 cells mL1 2.6 ± 12.2
Squamous cells% 5 ± 9.1
Neutro% pre 54.14 ± 10.10
Macro% pre 38.43 ± 8.74
Esino% pre 1.69 ± 1.15
Lymph% pre 7.81 ± 5.01
Exacerbation pre 5.57 ± 1.45
Intubation pre 4 (28.6%)
Table 2 Statin and control group at the end of study.
Statin (n= 14)
FEV1post 47.08 ± 9.48
FEF25post 59.99 ± 7.18
FEF50post 54.93 ± 7.64
FEF75post 36.78 ± 7.56
Leptin post (pg/mL) 87.00 ± 16.19
TCC 106 cells mL1 post 2.1 ± 3.21
Squamous cells% 5.8 ± 7.1
Neutro post 33.64 ± 7.43
Macro post 35.96 ± 11.7
Esino post 1.43 ± 0.69
Lymph post 9.93 ± 3.66
Exacerbation post 2.50 ± 0.76
Intubation post 2 (14.3%)cell count in induced sputum and exacerbation 10 months be-
fore introduction of statin.
After 10 months from statin there is signiﬁcant decrease of
total cell count in statin group and also high signiﬁcance de-
crease of sputum leptin, neutrophils and exacerbation in the
statin group compared to control group.
Also signiﬁcant decrease of total cell count in statin group
pre and at end of study, and high signiﬁcance decrease of lep-
tin, neutrophils and exacerbation of statin group pre introduc-
tion of statin and at end of study.
In control group there are no signiﬁcance changes in
control group at start and at end of study.
There was signiﬁcant positive effects of spiriva on sputum
leptin, and there were no signiﬁcant effects of BIPAP, oxygen,
ARB, ACE, ICS and spiriva on results of study.Discussion
Statins, inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A
reductase, are potent inhibitors of cholesterol biosynthesis and
have greatly improved the management of ischaemic heart
disease. Recent studies suggest that direct antithrombotic
and anti-inﬂammatory effects associated with treatment with
statins may at least partly account for the reduction ofControl (n= 14) P value
59.64 ± 7.22 0.372
46.64 ± 10.68 0.883
57.71 ± 10.00 0.500
53.93 ± 6.15 0.954
37.14 ± 5.93 0.786
182.07 ± 47.85 0.966
2.7 ± 12.9 0.966
5.3 ± 8.6 0.412
51.71 ± 8.87 0.505
38.21 ± 8.57 0.948
1.51 ± 0.75 0.645
8.34 ± 6.80 0.893
5.50 ± 1.51 0.899
3 (21.4%) 0.663
Control (n= 14) P value
46.33 ± 10.53 0.787
57.10 ± 10.12 0.531
53.62 ± 7.22 0.851
36.14 ± 5.35 0.796
176.29 ± 45.46 0.000
2.8 ± 9.44 0.05
6.3 ± 8.6 0.112
50.78 ± 9.93 0.000
37.11 ± 8.86 0.866
1.16 ± 0.52 0.253
9.41 ± 7.36 0.817
5.57 ± 1.83 0.000
5 (35.7%) 0.190
Table 3 PFT, sputum leptin, total, differential cell count and
exacerbation in statin group pre and post introduction of
statin.
Statin group Pre (n= 14) Post (n= 14) P value
FEV1 47.21 ± 9.58 47.08 ± 9.48 0.981
FEF25 59.86 ± 6.13 59.99 ± 7.18 0.910
FEF50 54.07 ± 6.73 54.93 ± 7.64 0.942
FEF75 36.50 ± 6.44 36.78 ± 7.56 0.996
Leptin (pg/mL) 181.29 ± 49.02 87.00 ± 16.19 0.000
TCC 106 cells mL1 2.6 ± 12.2 2.1 ± 3.21 0.05
Neutro 54.14 ± 10.10 33.64 ± 7.43 0.000
Macro 38.43 ± 8.74 35.96 ± 11.7 0.412
Esino 1.69 ± 1.15 1.16 ± 0.52 0.116
Lymph 7.81 ± 5.01 9.93 ± 3.66 0.213
Exacerbation 5.57 ± 1.45 2.50 ± 0.76 0.000
Intubation 4 (28.6%) 2 (14.3%) 0.157
Table 4 PFT, total and differential cell count and exacerba-
tion in control group pre and at end of study.
Control group Pre (n= 14) Post (n= 14) P value
FEV1 46.64 ± 10.68 45.33 ± 10.53 0.574
FEF25 57.71 ± 10.00 56.10 ± 10.12 0.440
FEF50 53.93 ± 6.15 53.62 ± 7.22 0.933
FEF75 37.14 ± 5.93 36.14 ± 5.35 0.395
Leptin (pg/mL) 182.07 ± 47.85 176.29 ± 45.46 0.11
TCC 106 cells mL1 2.7 ± 12.9 2.8 ± 9.44 0.915
Neutro 51.71 ± 8.87 50.78 ± 9.93 0.211
Macro 38.21 ± 8.57 37.11 ± 8.86 0.132
Esino 1.51 ± 0.75 1.16 ± 0.52 0.243
Lymph 8.34 ± 6.80 9.41 ± 7.36 0.082
Exacerbation 5.50 ± 1.51 5.57 ± 1.83 0.720
Intubation 3 (21.4%) 5 (35.7%) 0.414
Table 5 Effects of various drugs and BIPAP in signiﬁcant results.
Statin group ve Eﬀects
Leptin ICS (n= 5) 80.20 ± 11.65
NeutrophilICS 30.60 ± 6.27
TCC 106 cells mL1 4.7 ± 11.9
Exacerbation ICS 2.00 ± 0.71
Leptin spiriva (n= 5)72.60 ± 10.31
Neutrophil spiriva 32.20 ± 6.69
TCC 106 cells mL1 4.3 ± 11.9
Exacerbation spiriva 2.80 ± 0.84
Leptin O2 (n= 11) 85.27 ± 17.71
Neutrophil O2 32.36 ± 7.19
TCC 106 cells mL1 4.7 ± 16.7
Exacerbation O2 2.45 ± 0.82
Leptin BIPAP (n= 11) 85.27 ± 17.71
Neutrophil BIPAP 32.36 ± 7.19
TCC 106 cells mL1 4.9 ± 11.3
Exacerbation BIPAP 2.45 ± 0.82
Leptin ARB (n= 10) 84.30 ± 14.66
Neutrophil ARB 35.30 ± 8.08
TCC 106 cells mL1 4.9 ± 14.90
Exacerbation ARB 2.60 ± 0.70
Leptin ACE (n= 9)82.56 ± 18.23
Neutrophil ACE 33.44 ± 7.47
TCC 106 cells mL1 4.08 ± 3.57
Exacerbation ACE 2.44 ± 0.88
68 N.A. Rezk, A. Elewacardiovascular events. In particular, statins reduce high sensi-
tive C reactive protein (hs-CRP), tumour necrosis factor a, and
metalloproteinase 9 production [3].
Evidence of the value of reducing inﬂammation in COPD
patients as a therapeutic maneuver has been provided by stud-
ies demonstrating the efﬁcacy of inhaled corticosteroids such
as ﬂuticasone, [9] triamcinolone [10] and other agents of this
class. However, the recently published TORCH trial [11] pro-
vides data which question the efﬁcacy of ﬂuticasone propio-
nate in preventing death and suggest a possible increase in
the incidence of pneumonia in COPD patients.
Within the last few years, it has been suggested that the
anti-inﬂammatory properties of statins [12] may lead to their
utility in the treatment of other diseases in which inﬂammation
plays a role in pathogenesis [13]. Might statins have a place in
the treatment of COPD.
We aimed in this study to evaluate the role of statin in
reduction inﬂammation and its effect on lung function and
exacerbation .
We studied 28 patients with chronic obstructive lung dis-
ease. Fourteen patients (11 male and 3 female) receiving statin
due to hyperlipidemia, and other 14 patients patients (11 male
and 3 female) not hyperlipidemic .
All patients were EX smokers
There were no signiﬁcance between the two groups before
the introduction of statin. after 10 months from the introduc-
tion of statin, there were high signiﬁcant decrease of, neutro-
phils, sputum leptin and exacerbation and signiﬁcant decrease
of total cell count in sputum when compared to control
group and also when compared with statin group before
the introduction of statin, and this may explained by anti
inﬂammatory effects of statin, and hypolipidemic effects of
statin, this study agreed with retrospective study done by
[14] who studied 185 patients with COPD exacerbation, with
a 1-year follow-up, and found lower incidence of both+ve Eﬀects P value
(n= 9) 90.78 ± 17.69 0.257
35.33 ± 7.81 0.270
4.8 ± 9.44 0.912
2.78 ± 0.67 0.063
(n= 9)95.00 ± 13.08 0.007
34.44 ± 8.08 0.608
4.5 ± 9.44 0.815
2.33 ± 0.71 0.288
(n= 3) 93.33 ± 7.64 0.467
38.33 ± 7.64 0.231
4.8 ± 15.41 0.915
2.67 ± 0.58 0.686
(n= 3) 93.33 ± 7.64 0.467
38.33 ± 7.64 0.231
4.8 ± 9.2 0.817
2.67 ± 0.58 0.686
(n= 4) 93.75 ± 20.14 0.344
29.50 ± 3.32 0.082
4.7 ± 15.44 0.810
2.25 ± 0.96 0.458
(n= 5)95.00 ± 7.91 0.177
34.00 ± 8.22 0.900
4.66 ± 4.23 0.847
2.60 ± 0.55 0.729
Anti inﬂammatory effects of statin in COPD 69exacerbations and intubations in patients with COPD. This
anti inﬂammatory effects of statin proved in several studies,
[15] who found statin use reduce of the frequency of
CD4 + CD28 T lymphocytes in patients with unstable angi-
na and conﬁrm an association between statin use and reduced
concentrations of hs-CRP. CD4 + CD28null T cells. And
[16] who using a retrospective cohort design, 854 consecutive
patients (mean age 70.8 years; 51.5% female) with a diagnosis
of COPD exacerbation were included in the study at dis-
charge from a Norwegian teaching hospital and found that
Treatment with statins was associated with improved survival
after chronic obstructive pulmonary disease exacerbation,
while inhaled corticosteroids appeared to increase the survival
beneﬁt associated with statin use.
Also our study agreed with [18] who studied 1687 patients
(mean age 70.6 years) were followed, including 596 statin users
and 1091 non-users, and conclude Statin use is associated with
a 30% reduction in all-cause mortality at 3–4 years after ﬁrst
admission for COPD, irrespective of a past history of cardio-
vascular disease and diabetes.
And [19] who studied rats exposed to cigarette smoke for
16 weeks, morphologic changes in the lungs and pulmonary
arterial pressure were examined. And conclude Simvastatin
ameliorated the structural and functional derangements of
the lungs caused by cigarette smoking, partly by suppressing
inﬂammation and matrix metalloproteinase-9 induction and
preventing pulmonary vascular abnormality. These ﬁndings
indicate that statins may play a role in the treatment of ciga-
rette smoking-induced chronic obstructive pulmonary disease.
Also we agreed with [20] who make Medline, Excerpta
Medica Database, Papers First, and the Cochrane collabora-
tion and Cochrane Register of controlled trials were searched.
Randomized controlled trials (RCTs), observational cohort
studies, case-control studies, and population-based analyses
were considered for inclusion. And conclude that The current
literature collectively suggests that statins may have a beneﬁ-
cial role in the treatment of COPD. However, the majority
of published studies have inherent methodological limitations
of retrospective studies and population-based analyses. There
is a need for prospective interventional trials designed speciﬁ-
cally to assess the impact of statins on clinically relevant out-
comes in COPD.
There was positive effects of spiriva on lowering the leptin
and other drugs (BIPAP, O2, ARB, ACE, ICS) has not any
effects on the results
We conclude that statin may lower the exacerbation in
patients with chronic obstructive lung diseases and may lower
the total cell count of inﬂammatory cells, sputum leptin and
neutrophils.
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